Nanoliposomes Co-Encapsulating CT Imaging Contrast Agent and Photosensitizer for Enhanced, Imaging Guided Photodynamic Therapy of Cancer

Overview

Journal Theranostics

Date 2019 Mar 15

PMID 30867833

Citations 23

Authors

Hao Xu

Tymish Y Ohulchanskyy

Artem Yakovliev

Roman Zinyuk

Jun Song

Liwei Liu

Junle Qu

Zhen Yuan

Affiliations

Soon will be listed here.

Abstract

Fluorescence (FL) and X-ray computed tomography (CT) imaging-guided photodynamic therapy (PDT) can provide a powerful theranostic tool to visualize, monitor, and treat cancer and other diseases with enhanced accuracy and efficacy. In this study, clinically approved iodinated CT imaging contrast agent (CTIA) iodixanol and commercially available photosensitizer (PS) meso-tetrakis (4-sulphonatophenyl) porphine (TPPS) were co-encapsulated in biocompatible PEGylated nanoliposomes (NL) for enhanced anticancer PDT guided by bimodal (FL and CT) imaging. The NL co-encapsulation of iodixanol and TPPS (LIT) lead to an increase in singlet oxygen generation by PS via the intraparticle heavy-atom (iodine) effect on PS molecules, as it was confirmed by both direct and indirect measurements of singlet oxygen production. The confocal imaging and PDT of cancer cells were performed , exhibiting the cellular uptake of TPPS formulations and enhanced PDT efficacy of LIT. Meanwhile, bimodal (FL and CT) imaging was also conducted with tumor-bearing mice and the imaging results manifested high-efficient accumulation and retention of LIT in tumors. Moreover, PDT of tumor was shown to be drastically more efficient with LIT than with other formulations of TPPS. This study demonstrated that LIT can serve as a highly efficient theranostic nanoplatform for enhanced anticancer PDT guided by bimodal (FL and CT) imaging.

Citing Articles

Navigating the Clinical Landscape of Liposomal Therapeutics in Cancer Treatment.

Kozak A, Lavrih E, Mikhaylov G, Turk B, Vasiljeva O Pharmaceutics. 2025; 17(2).

PMID: 40006643 PMC: 11859495. DOI: 10.3390/pharmaceutics17020276.

NIR-II light-activated two-photon squaric acid dye with Type I photodynamics for antitumor therapy.

Wang K, Xu Y, Chen Z, Li H, Hu R, Qu J Nanophotonics. 2024; 11(22):5089-5100.

PMID: 39634301 PMC: 11501322. DOI: 10.1515/nanoph-2022-0482.

Combining near infrared fluorescence and laser speckle imaging with optical tissue clearing for in vivo transcranial monitoring of cerebral blood vessels damaged by photodynamic nanoformulation.

Liu J, Xu H, Gao S, Liu L, Qu J, Ohulchanskyy T Biomed Opt Express. 2024; 15(2):924-937.

PMID: 38404313 PMC: 10890862. DOI: 10.1364/BOE.513820.

Advances in nanotechnology-based targeted-contrast agents for computed tomography and magnetic resonance.

Lai J, Luo Z, Chen L, Wu Z Sci Prog. 2024; 107(1):368504241228076.

PMID: 38332327 PMC: 10854387. DOI: 10.1177/00368504241228076.

Liposomes for Cancer Theranostics.

Fernandes D Pharmaceutics. 2023; 15(10).

PMID: 37896208 PMC: 10610083. DOI: 10.3390/pharmaceutics15102448.

References

Kim S, Ohulchanskyy T, Pudavar H, Pandey R, Prasad P . Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc. 2007; 129(9):2669-75. PMC: 2556058. DOI: 10.1021/ja0680257. View

Xie J, Lee S, Chen X . Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62(11):1064-79. PMC: 2988080. DOI: 10.1016/j.addr.2010.07.009. View

Barenholz Y . Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160(2):117-34. DOI: 10.1016/j.jconrel.2012.03.020. View

Kepshire D, Mincu N, Hutchins M, Gruber J, Dehghani H, Hypnarowski J . A microcomputed tomography guided fluorescence tomography system for small animal molecular imaging. Rev Sci Instrum. 2009; 80(4):043701. PMC: 2678792. DOI: 10.1063/1.3109903. View

Glidden M, Celli J, Massodi I, Rizvi I, Pogue B, Hasan T . Image-Based Quantification of Benzoporphyrin Derivative Uptake, Localization, and Photobleaching in 3D Tumor Models, for Optimization of PDT Parameters. Theranostics. 2012; 2(9):827-39. PMC: 3475211. DOI: 10.7150/thno.4334. View

DMello S, Cruz C, Chen M, Kapoor M, Lee S, Tyner K . The evolving landscape of drug products containing nanomaterials in the United States. Nat Nanotechnol. 2017; 12(6):523-529. DOI: 10.1038/nnano.2017.67. View

Spring B, Bryan Sears R, Zheng L, Mai Z, Watanabe R, Sherwood M . A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat Nanotechnol. 2016; 11(4):378-87. PMC: 4821671. DOI: 10.1038/nnano.2015.311. View

. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002; 22(1):6-18. DOI: 10.1097/00006982-200202000-00003. View

Roy I, Ohulchanskyy T, Pudavar H, Bergey E, Oseroff A, Morgan J . Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc. 2003; 125(26):7860-5. DOI: 10.1021/ja0343095. View

10.

Mallidi S, Anbil S, Lee S, Manstein D, Elrington S, Kositratna G . Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema. J Biomed Opt. 2014; 19(2):028001. PMC: 3915169. DOI: 10.1117/1.JBO.19.2.028001. View

11.

Lucky S, Soo K, Zhang Y . Nanoparticles in photodynamic therapy. Chem Rev. 2015; 115(4):1990-2042. DOI: 10.1021/cr5004198. View

12.

Oh M, Lee N, Kim H, Park S, Piao Y, Lee J . Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided sentinel lymph node mapping. J Am Chem Soc. 2011; 133(14):5508-15. DOI: 10.1021/ja200120k. View

13.

Fan W, Huang P, Chen X . Overcoming the Achilles' heel of photodynamic therapy. Chem Soc Rev. 2016; 45(23):6488-6519. DOI: 10.1039/c6cs00616g. View

14.

Derycke A, de Witte P . Liposomes for photodynamic therapy. Adv Drug Deliv Rev. 2004; 56(1):17-30. DOI: 10.1016/j.addr.2003.07.014. View

15.

Celli J, Spring B, Rizvi I, Evans C, Samkoe K, Verma S . Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010; 110(5):2795-838. PMC: 2896821. DOI: 10.1021/cr900300p. View

16.

Lim C, Shin J, Kwon I, Jeong S, Kim S . Iodinated photosensitizing chitosan: self-assembly into tumor-homing nanoparticles with enhanced singlet oxygen generation. Bioconjug Chem. 2012; 23(5):1022-8. DOI: 10.1021/bc300012g. View

17.

Obaid G, Broekgaarden M, Bulin A, Huang H, Kuriakose J, Liu J . Photonanomedicine: a convergence of photodynamic therapy and nanotechnology. Nanoscale. 2016; 8(25):12471-503. PMC: 4956486. DOI: 10.1039/c5nr08691d. View

18.

Laubach H, Chang S, Lee S, Rizvi I, Zurakowski D, Davis S . In-vivo singlet oxygen dosimetry of clinical 5-aminolevulinic acid photodynamic therapy. J Biomed Opt. 2008; 13(5):050504. PMC: 2994192. DOI: 10.1117/1.2981813. View

19.

Lim C, Shin J, Lee Y, Kim J, Park H, Kwon I . Heavy-atomic construction of photosensitizer nanoparticles for enhanced photodynamic therapy of cancer. Small. 2010; 7(1):112-8. DOI: 10.1002/smll.201001358. View

20.

Jezek P, Nekvasil M, Skobisova E, Urbankova E, Jirsa M, Zadinova M . Experimental photodynamic therapy with MESO-tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice. Int J Cancer. 2002; 103(5):693-702. DOI: 10.1002/ijc.10857. View